Company Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.
The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations.
The company was incorporated in 2016 and is headquartered in Montreal, Canada.
| Country | CA |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 179 |
| CEO | Lloyd Mitchell Segal |
Contact Details
Address: 7210 Frederick-Banting Montreal, QC CA | |
| Website | https://www.reparerx.com |
Stock Details
| Ticker Symbol | RPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001808158 |
| CUSIP Number | 760273102 |
| ISIN Number | US7602731025 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Mitchell Segal | President, Chief Executive Officer & Director |
| Steve Forte CPA | Executive Vice President & Chief Financial Officer |
| Cameron Black Ph.D. | Executive Vice President of Discovery |
| Daniel Belanger | Executive Vice President of Human Resource |
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Maria Koehler M.D., Ph.D. | Executive Vice President & Chief Medical Officer |
| Dr. Michael Zinda Ph.D. | Executive Vice President & Chief Scientific Officer |
| Philip Herman | Executive Vice President, Chief Commercial & Portfolio Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 424B5 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 07, 2024 | 8-K | Current Report |
| Aug 06, 2024 | S-3 | Filing |